Skip to main content

Advertisement

SpringerLink
Log in

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Cisplatin is commonly used in non-small-cell lung cancer (NSCLC) chemotherapy; however, chemoresistance to cisplatin remains a great clinical challenge. Octamer-binding protein 4 (OCT4) has been reported to be overexpressed in NSCLC. In this study, we aimed to investigate the potential role of OCT4 in NSCLC with chemoresistance to cisplatin.

Methods

Expressions of OCT4 was detected in NSCLC tissues and cell lines. We utilized siRNA to knock down OCT4 expression in human NSCLC cells and analyzed their phenotypic changes.

Results

We found that the difference of OCT4 expression between NSCLC and the adjacent non-tumourous tissues was statistically significant. Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by cisplatin, suggesting OCT4 may contribute to cisplatin resistance in NSCLC.

Conclusion

Our findings indicate that targeting OCT4 could improve cisplatin effect in NSCLC, confirming their role in modulating cisplatin sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13:287–97.

    PubMed  Google Scholar 

  2. Tassinari D, Carloni F, Santelmo C, Tamburini E, Lazzari Agli L, Tombesi P, et al. Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. Rev Recent Clin Trials. 2009;4:27–33.

    Article  CAS  PubMed  Google Scholar 

  3. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–34.

    Article  CAS  PubMed  Google Scholar 

  4. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

    Article  CAS  PubMed  Google Scholar 

  5. Brugger W, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113–20.

    Article  CAS  PubMed  Google Scholar 

  6. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133positive cells. PLoS One. 2008;3:e2637.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Li XL, Jia LL, Shi MM, Li X, Li ZH, Li HF, et al. Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression. J Transl Med. 2013;11:232.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y, et al. Expression of sox2 and oct4 and their clinical significance in human non-small-cell lung cancer. Int J Mol Sci. 2012;13:7663–75.

  9. Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou CX, Zhang C, Zhang Z, Li X. The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol. 2013;8:145.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340–6.

    Article  CAS  PubMed  Google Scholar 

  11. Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer. 2008;98:907–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

    Article  CAS  PubMed  Google Scholar 

  13. Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, et al. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer. 2016;98:76–8.

    Article  PubMed  Google Scholar 

  14. Kim JB, Greber B, Araúzo-Bravo MJ, Meyer J, Park KI, Zaehres H, et al. Direct reprogramming of human neural stem cells by OCT4. Nature. 2009;461:649–53.

    Article  CAS  PubMed  Google Scholar 

  15. Zeineddine D, Hammoud AA, Mortada M, Boeuf H. The Oct4 protein: more than a magic stemness marker. Am J Stem Cells. 2014;3:74.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y, et al. Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol. 2011;223:672–82.

    Article  CAS  PubMed  Google Scholar 

  17. Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9:295–302.

    Article  CAS  PubMed  Google Scholar 

  18. Wen J, Park JY, Park KH, Chung HW, Bang S, Park SW, et al. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas. 2010;39:622–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Key Laboratory of Cancer Prevention and Therapy, The Second Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin, 300060, China

    X. Liu, M. Ma, X. Duan, H. Zhang & M. Yang

Authors
  1. X. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Liu.

Ethics declarations

Conflict of interest

There is no conflict of interests to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Ma, M., Duan, X. et al. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Clin Transl Oncol 19, 587–592 (2017). https://doi.org/10.1007/s12094-016-1569-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-016-1569-y

Keywords

Search

Navigation